GlassScriptPhysician profile
Shivshankar Navada
NPI 1740286327
$4,447.53
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $884 · 2021: $1,046 · 2022: $1,016 · 2023: $890 · 2024: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,038.22 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $847.94 | 2021-2024 | |
| Ucb, INC. | $568.32 | 2019-2023 | Briviact |
| Lilly USA, LLC | $282.68 | 2019-2022 | |
| Amgen INC. | $256.66 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $252.77 | 2020-2024 | Ajovy, Austedo Xr, Austedo |
| Allergan, INC. | $246.49 | 2019-2021 | |
| Pfizer INC. | $214.23 | 2021-2024 | |
| Sk Life Science, INC. | $210.95 | 2020-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $159.09 | 2022 | |
| Upsher-Smith Laboratories LLC | $150.86 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $149.85 | 2021-2023 | Ultomiris |
| Kyowa Kirin, INC. | $149.08 | 2020-2022 | |
| Biogen, INC. | $131.91 | 2019-2021 | |
| Abbott Laboratories | $118.47 | 2019-2021 | |
| Genzyme Corporation | $68.06 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $61.81 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $59.66 | 2021-2023 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $54.49 | 2019-2023 | |
| Tanabe Pharma America, INC. | $54.03 | 2022-2023 | |
| Greenwich Biosciences, INC. | $51.75 | 2019 | |
| Amneal Pharmaceuticals LLC | $50.63 | 2019-2023 | Rytary |
| Argenx US, INC. | $48.41 | 2022-2023 | Vyvgart |
| Neurelis, INC. | $41.02 | 2020-2021 | |
| Lundbeck LLC | $38.29 | 2022 | |
| Eisai INC. | $37.62 | 2024 | |
| Celgene Corporation | $21.27 | 2022 | |
| Janssen Pharmaceuticals, INC | $21.13 | 2022 | |
| Adamas Pharmaceuticals, INC. | $19.80 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.78 | 2020 | |
| Emd Serono, INC. | $16.59 | 2021 | |
| Livanova USA, INC. | $16.55 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.85 | 2019 | |
| Acorda Therapeutics, INC | $14.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivshankar Navada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.